Morphic Holding, Inc. Stock price

Equities

MORF

US61775R1059

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
35.2 USD +2.36% Intraday chart for Morphic Holding, Inc. +1.59% +21.88%
Sales 2024 * 200K Sales 2025 * 750K Capitalization 1.76B
Net income 2024 * -196M Net income 2025 * -225M EV / Sales 2024 * 6,008 x
Net cash position 2024 * 560M Net cash position 2025 * 540M EV / Sales 2025 * 1,628 x
P/E ratio 2024 *
-9.04 x
P/E ratio 2025 *
-8.31 x
Employees 121
Yield 2024 *
-
Yield 2025 *
-
Free-Float 82.78%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.36%
1 week+1.59%
Current month-4.74%
1 month-6.31%
3 months+18.60%
6 months+56.51%
Current year+21.88%
More quotes
1 week
31.78
Extreme 31.78
35.53
1 month
31.78
Extreme 31.78
40.00
Current year
26.03
Extreme 26.03
41.47
1 year
19.35
Extreme 19.345
63.08
3 years
19.23
Extreme 19.23
68.75
5 years
9.90
Extreme 9.9
93.00
10 years
9.90
Extreme 9.9
93.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 15-06-30
President 55 15-12-31
Director of Finance/CFO 48 20-04-05
Members of the board TitleAgeSince
Founder 76 14-07-31
Director/Board Member 68 19-05-31
Director/Board Member 59 19-04-30
More insiders
Date Price Change Volume
24-03-28 35.2 +2.36% 344,168
24-03-27 34.39 +4.91% 285,985
24-03-26 32.78 +1.96% 366,184
24-03-25 32.15 -3.28% 353,918
24-03-22 33.24 -4.07% 236,813

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). It has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
35.2 USD
Average target price
56.75 USD
Spread / Average Target
+61.22%
Consensus
  1. Stock
  2. Equities
  3. Stock Morphic Holding, Inc. - Nasdaq